Trial results for the study investigating nivolumab plus ipilimumab in patients with salivary gland cancer were posted on ClinicalTrials.gov on 2025-12-18. The study observed responses in participants with both adenoid cystic carcinoma and other histologies of recurrent/metastatic salivary gland cancer.
Background
The study aimed to evaluate the effects of treatment with two drugs, nivolumab and ipilimumab, in participants diagnosed with salivary gland cancer.
Trial design
The study (NCT03172624) was a Phase 2, completed trial that enrolled 64 participants. It investigated the combination of nivolumab and ipilimumab in patients with salivary gland cancer.
Key results
The trial evaluated the Best Overall Response Rate in participants with recurrent/metastatic salivary gland cancer.
- In the R/M Adenoid Cystic Carcinoma (ACC) group, 2 participants demonstrated a best overall response. Other observed participant counts for Best Overall Response Rate in this group included 17 participants, 13 participants, and 0 participants.
- In the R/M SGC of Any Histology, Except ACC (Non ACC) group, 5 participants demonstrated a best overall response. Other observed participant counts for Best Overall Response Rate in this group included 8 participants, 18 participants, and 1 participant.
These counts represent different categories of response within the overall assessment.
What this means
The observed responses in both adenoid cystic carcinoma and other histologies of recurrent/metastatic salivary gland cancer suggest that the combination of nivolumab and ipilimumab may have activity in this patient population. These results provide initial insights into the potential utility of this immunotherapy combination for salivary gland cancer, an area with unmet medical needs.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03172624, titled "Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer," were posted on 2025-12-18 on clinicaltrials.gov.